Negative attitude towards medication is associated with working memory impairment in schizophrenia patients

International Clinical Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 93-96

  Goodman, Craig ^a,b,c   Knoll, Gabriella ^a,b   Isakov, Victoria ^a,b   Silver, Henry ^a,b,c  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b Mobile Post Hefer 38814   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cognition; Drug attitude; Forensic; Insight; Medication; Schizophrenia; Working memory

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FINGER SPAN TEST; FORENSIC PSYCHIATRY; HOSPITAL PATIENT; HUMAN; ISRAEL; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATIENT ATTITUDE; PENN INHIBITION TEST; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL; VERBAL MEMORY; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE; COGNITION; HUMANS; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 14844353928     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200503000-00005     Document Type: Article

References (26)

1. Amador XF, Raum M, Andreasen NC, Strauss DH, Yale SA, Clark S, Gorman JM (1994). Awareness of illness in schizophrenia, schizoaffective and mood disorders. Arch Gen Psychiatry 51:826-836.
2. Andreasen NC (1983). Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: The University of Iowa.
3. Andreasen NC (1984). Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa.
4. Awad GA (1993). Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19:609-618.
5. Baddeley A, Gathercole S, Papagno C (1998). The phonological loop as a language learning device. Psychol Rev 105:158-173.
6. Benton AL, Hannay HJ, Varney NR (1975). Visual perception of line direction in patients with unilateral brain disease. Neurology 25:907-910.
7. Cuffel BJ, Alford J, Fischer EP, Owen RR (1996). Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis 184:653-659.
8. Drake RE, Osher FC, Wallach MA (1989). Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis 177: 408-414.
9. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-Mental State'. J Psychiatr Res 12:189-198.
10. Glahn DC, Gur RC, Ragland JD, Censits DM, Gur RE (1997). Reliability, performance characteristics, construct validity, and an initial clinical application of a visual object learning test (VOLT). Neuropsychology 11:602-612.
11. Glahn DC, Cannon TD, Gur RE, Ragland JD, Gur RC (2000). Working memory constrains abstraction in schizophrenia. Biol Psychiatry 47:34-42.
12. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26:119-136.
13. Gur RC, Jaggi JL, Ragland JD, Resnick SM, Shtasel D, Muenz L, et al. (1993). Effects of memory processing on regional brain activation: cerebral blood flow in normal subjects. Int J Neurosci 72:31-44.
14. Gur RC, Ragland JD, Moberg PJ, Bilker WB, Kohler C, Siegel SJ, et al. (2001). Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology 25:777-788.
15. Guy W (1976). ECDU Assessment Manual for Psychopharmacology, rev. edn. Department of Health Education and Welfare publication (ADM) 76-338. Rockville MD: National Institute of Mental Health, pp. 534-537.
16. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV (2003). Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophren Res 63:49-58.
17. Loffler W, Kilian R, Toumi M, Angermeyer MC (2003). Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 36:105-11 2.
18. Patterson TL, Lacro J, McKibbin CL, Moscona S, Hughes T, Jeste DV (2002). Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol 22:11-19.
19. Razali MS, Yahya H (1995). Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand 91:331-335.
20. Sevy S, Nathanson K, Visweswaraiah H, Amador X (2004). The relationship between insight and symptoms in schizophrenia. Compr Psychiatry 45:16-19.
21. Silver H, Feldman P, Bilker W, Gur RC (2003). Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 160:1809-1816.
22. Simpson GM, Angus JWS (1970). A rating scale for ertrapyramidal side effects. Acta Psychiatr Scand (Suppl) 212:11-19.
23. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, Israel LM, et al. (1999). The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 187:102-108.
24. Wechsler D (1955). Wechsler Adult Intelligence Manual. New York, NY: Psychological Corporation.
25. Young JL, Spitz RT, Hillbrand M, Daneri G (1999). Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects. J Am Acad Psychiatry Law 27:426-444.
26. Zygmunt A, Olfson M, Boyer CA, Mechanic D (2002). Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 159:1653-1664.